학술논문
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Document Type
Article
Author
Source
American Journal of Hematology; Dec2023, Vol. 98 Issue 12, pE364-E368, 5p
Subject
Language
ISSN
03618609